On November 20, 2019, Aevi Genomic Medicine, Inc. dosed the first patient with AEVI-002 in a Phase Ib clinical trial (MDGN-002-CD-101 TRaCKLIGHT) for patients with moderate to severe active Crohn’s Disease. AEVI-002 is a potential first-in-class anti-LIGHT monoclonal antibody being developed for use in Pediatric Onset Crohn’s disease. The 8-week Phase Ib, open-label, multi-center, dose-escalation proof-of-concept study has been initiated and is currently recruiting and enrolling patients.